55 / 69
55
8.
Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A,
Hehlmann R, et al. Heterogeneous prognostic impact of
derivative chromosome 9 deletions in chronic
myelogenous leukemia. Blood 2007; 110:1283-90.
9.
Ghaith F, Abdou S, El-Bendary A, Shahin D, Eid M,
Megeed WA, et al. Prognostic relevance of 9q34 deletion
and the suppressor of cytokine signalling-1 in CML
patients. Int J Lab Hematol 2010;32:103-12.
10.
Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F,
Amariglio N, Rechavi G, et al. Subgroup of patients with
Philadelphia-positive chronic myelogenous leukemia
characterized by a deletion of 9q proximal to ABL gene:
expression profiling, resistance to interferon therapy, and
poor prognosis. Cancer Genet Cytogenet 2001;128:114-9.
11.
Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E,
Abruzzo LV, Verstovsek S, et al. Prognostic impact of
deletions of derivative chromosome 9 in patients with
chronic myelogenous leukemia treated with nilotinib or
dasatinib. Cancer 2011;117:5085-93.
12. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S,
Garcia-Manero G, Verstovsek S, et al. Imatinib mesylate
therapy may overcome the poor prognostic significance of
deletions of derivative chromosome 9 in patients with
chronic myelogenous leukemia. Blood 2005;105:2281-6.
13.
Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N,
Shepherd P, et al. Deletions of the derivative chromosome
9 occur at the time of the Philadelphia translocation and
provide a powerful and independent prognostic indicator
in chronic myeloid leukemia. Blood 2001;98:1732-8.
14.
Fourouclas N, Campbell PJ, Bench AJ, Swanton S, Baxter
EJ, Huntly BJ, et al. Size matters: the prognostic
implications of large and small deletions of the derivative
9 chromosome in chronic myeloid leukemia.
Haematologica 2006;91:952-5.